These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38950781)

  • 1. Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/factor VIII concentrate.
    Iorio A; James P; Ma A; Srivastava A
    J Thromb Haemost; 2024 Oct; 22(10):2739-2744. PubMed ID: 38950781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.
    Nowak-Göttl U; Krümpel A; Russo A; Jansen M
    Haemophilia; 2013 Nov; 19(6):887-92. PubMed ID: 23919249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
    Reynen E; James P
    Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
    Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
    Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and delivery in women with von Willebrand disease.
    Castaman G; James PD
    Eur J Haematol; 2019 Aug; 103(2):73-79. PubMed ID: 31107984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience.
    Khair K; Batty P; Riat R; Bowles L; Burgess C; Chen YH; Hart D; Platton S; Pasi J; Liesner R
    Haemophilia; 2015 Jan; 21(1):e44-50. PubMed ID: 25112927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.